X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pralatrexate (109) 109
index medicus (68) 68
humans (63) 63
oncology (50) 50
aminopterin - analogs & derivatives (41) 41
methotrexate (32) 32
hematology (26) 26
aminopterin - therapeutic use (25) 25
t-cell lymphoma (22) 22
chemotherapy (21) 21
male (21) 21
pharmacology & pharmacy (21) 21
phase-ii trial (21) 21
female (20) 20
folic acid antagonists - therapeutic use (20) 20
t cells (20) 20
aged (19) 19
peripheral t-cell lymphoma (19) 19
romidepsin (19) 19
antineoplastic agents - therapeutic use (18) 18
cancer (18) 18
adult (17) 17
lymphoma, t-cell, peripheral - drug therapy (17) 17
middle aged (17) 17
antifolate (16) 16
medicine & public health (16) 16
non-hodgkin's lymphomas (16) 16
aminopterin - administration & dosage (15) 15
gemcitabine (15) 15
lymphoma (15) 15
antineoplastic combined chemotherapy protocols - therapeutic use (14) 14
brentuximab vedotin (14) 14
cutaneous t-cell lymphoma (14) 14
open-label (14) 14
treatment outcome (14) 14
animals (12) 12
lymphomas (12) 12
10-propargyl-10-deazaaminopterin (11) 11
aminopterin - adverse effects (11) 11
care and treatment (11) 11
phase-ii (11) 11
10-deazaaminopterin (10) 10
bortezomib (10) 10
clinical trials as topic (10) 10
hematology, oncology and palliative medicine (10) 10
histone deacetylase inhibitors (10) 10
lymphoma, t-cell, cutaneous - drug therapy (10) 10
skin neoplasms - drug therapy (10) 10
aminopterin - pharmacokinetics (9) 9
dose-response relationship, drug (9) 9
folic acid (9) 9
lymphoma, t-cell - drug therapy (9) 9
sezary-syndrome (9) 9
transplantation (9) 9
aged, 80 and over (8) 8
aminopterin - pharmacology (8) 8
article (8) 8
classification (8) 8
denileukin diftitox (8) 8
expression (8) 8
folic acid antagonists - administration & dosage (8) 8
folic acid antagonists - adverse effects (8) 8
folic acid antagonists - pharmacokinetics (8) 8
histone deacetylase inhibitor (8) 8
malignancies (8) 8
mycosis fungoides (8) 8
peripheral t cell lymphoma (8) 8
pharmacology/toxicology (8) 8
10-deaza-aminopterin series (7) 7
cancer research (7) 7
drug therapy (7) 7
folic acid antagonists - pharmacology (7) 7
hemic and lymphatic diseases (7) 7
high-affinity (7) 7
neoplasm recurrence, local - drug therapy (7) 7
neoplasms - drug therapy (7) 7
reduced folate carrier (7) 7
therapy (7) 7
abridged index medicus (6) 6
alemtuzumab (6) 6
analysis (6) 6
antineoplastic agents - pharmacology (6) 6
antitumor-activity (6) 6
bexarotene (6) 6
dihydrofolate reductase (6) 6
drug administration schedule (6) 6
drug resistance, neoplasm (6) 6
leucovorin (6) 6
lymphoma, t-cell, peripheral - pathology (6) 6
methotrexate - pharmacology (6) 6
models (6) 6
multicenter (6) 6
mycosis-fungoides (6) 6
non-hodgkin-lymphoma (6) 6
non-hodgkins-lymphoma (6) 6
patients (6) 6
pemetrexed (6) 6
pharmacology (6) 6
prognostic-factors (6) 6
single-agent (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 01/2015, Volume 33, Issue 3_suppl, pp. 152 - 152
152 Background: Advanced EGC is an aggressive cancer with limited treatment (Rx) options. In preclinical studies P has demonstrated increased cellular uptake... 
Journal Article
Australian prescriber, ISSN 0312-8008, 04/2019, Volume 42, Issue 2, pp. 77 - 77
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 07/2019
Journal Article
Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 11/2018, Volume 18, Issue 11, pp. e445 - e447
Cutaneous T-cell lymphomas (CTCL) are rare, heterogeneous non-Hodgkin lymphomas with poor prognoses. Treatment options for CTCL are limited by their efficacy... 
Therapy | Leucovorin | Mucositis | Lymphoma | Pralatrexate | ONCOLOGY | HEMATOLOGY
Journal Article
BLOOD, ISSN 0006-4971, 08/2019, Volume 134, Issue 8, pp. 678 - 687
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an uncommon hematologic malignancy with poor outcomes. Existing data on the clinical behavior of BPDCN... 
REARRANGEMENT | MYELOID NEOPLASMS | CLASSIFICATION | PRALATREXATE | MUTATIONS | IDENTIFICATION | HEMATOLOGY | WORLD-HEALTH-ORGANIZATION | LEUKEMIC PRESENTATION | REVEALS | TRANSPLANTATION
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 10/2019, Volume 60, Issue 12, pp. 2927 - 2930
Peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) are rare, heterogeneous non-Hodgkin lymphomas with poor prognoses. Pralatrexate has... 
peripheral T-cell lymphoma | skin reactions | pralatrexate | Mucositis | leucovorin | cutaneous T-cell lymphoma
Journal Article
Haematologica, ISSN 0390-6078, 05/2019, Volume 104, Issue 5, pp. 993 - 1003
Mogamulizumab, a humanized defucosylated anti-C-C chemokine receptor 4 monoclonal antibody, has been approved in Japan for the treatment of C-C chemokine... 
LEUKEMIA-LYMPHOMA | REVEALS MARKED ACTIVITY | LENALIDOMIDE | RETROVIRUS | MONOCLONAL-ANTIBODY KW-0761 | PHASE-II | JAPANESE | PRALATREXATE | HEMATOLOGY | EXPRESSION | TRANSPLANTATION
Journal Article
Journal Article
Journal Article
Clinical Lymphoma Myeloma and Leukemia, ISSN 2152-2650, 09/2017, Volume 17, pp. S168 - S169
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 09/2019, Volume 178, pp. 329 - 340
A novel series of 6-substituted pyrrolo[2,3- ]pyrimidines with reversed amide moieties from the lead compound were designed and synthesized as nonclassical... 
Antifolates | Antiproliferation | DHFR | pyrrolo[2,3-d]pyrimidines | Molecular modeling | CHEMISTRY, MEDICINAL | SERIES | METHOTREXATE | PHARMACOKINETICS | PHARMACOLOGY | DHFR INHIBITORS SYNTHESIS | RESISTANCE | PRALATREXATE | Pyrimidines | Dihydrofolate reductase | Methotrexate | Pemetrexed | Analysis
Journal Article
Cancer, ISSN 0008-543X, 11/2016, Volume 122, Issue 21, pp. 3297 - 3306
BACKGROUND The objective of this phase 1 and 2 trial was to identify the appropriate dose of combined carboplatin and pralatrexate for patients with recurrent,... 
pharmacokinetics | carboplatin‐pralatrexate | chemotherapy | recurrent ovarian cancer | carboplatin-pralatrexate | GYNECOLOGIC-ONCOLOGY-GROUP | ANTIFOLATE | T-CELL LYMPHOMA | TOXICITY | STAGE-III | PACLITAXEL | TRIAL | CISPLATIN | ONCOLOGY | 10-PROPARGYL-10-DEAZAAMINOPTERIN | Prognosis | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Cystadenocarcinoma, Serous - pathology | Cystadenocarcinoma, Serous - drug therapy | Neoplasm Recurrence, Local - pathology | Tissue Distribution | Peritoneal Neoplasms - drug therapy | Adult | Female | Aminopterin - analogs & derivatives | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Carcinosarcoma - pathology | Peritoneal Neoplasms - pathology | Neoplasm Invasiveness | Carboplatin - administration & dosage | Fallopian Tube Neoplasms - pathology | Survival Rate | Aminopterin - administration & dosage | Carcinoma, Transitional Cell - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Transitional Cell - drug therapy | Endometrial Neoplasms - drug therapy | Endometrial Neoplasms - pathology | Aged | Carcinosarcoma - drug therapy | Neoplasm Staging | Usage | Care and treatment | Cancer patients | Carboplatin | Fallopian tubes | Dosage and administration | Diagnosis | Health aspects | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, ISSN 0889-8588, 08/2019, Volume 33, Issue 4, pp. 657 - 657
Therapeutic advances for peripheral T-cell non-Hodgkin lymphoma (PTCL) have lagged behind their B-cell NHL counterparts in part because novel agents to treat... 
Targeted therapy | TET2 | PHASE-II | BRENTUXIMAB VEDOTIN SGN-35 | OPEN-LABEL | RHOA | SINGLE-AGENT | ONCOLOGY | IMMUNOTHERAPY | DNA methylation | MUTATIONS | PRALATREXATE | Jak/STAT pathway | INHIBITOR | HEMATOLOGY | T-cell lymphoma
Journal Article
BRITISH JOURNAL OF HAEMATOLOGY, ISSN 0007-1048, 04/2016, Volume 173, Issue 2, pp. 253 - 259
Pralatrexate inhibits folic acid metabolism, and preclinical studies have shown that it is cytotoxic to multiple myeloma cells. This phase 1 study investigated... 
refractory | multiple myeloma | DEXAMETHASONE | COMBINATION THERAPY | HIGH-AFFINITY | METHOTREXATE | POMALIDOMIDE | CANCER | CHEMOTHERAPY | relapsed | LENALIDOMIDE | MALIGNANCIES | LYMPHOMA | pralatrexate | bortezomib | HEMATOLOGY
Journal Article
MEDICINE, ISSN 0025-7974, 07/2019, Volume 98, Issue 30, p. e16482
Rationale: Relapsed or refractory peripheral T-cell lymphomas are aggressive diseases. Pralatrexate is an antimetabolite. Hereby, we are reporting a... 
PTCL-NOS | MEDICINE, GENERAL & INTERNAL | peripheral T-cell lymphoma | pralatrexate | response | Case studies | Drug therapy | T cell lymphoma | Patient outcomes
Journal Article
Journal Article
CLINICAL NUCLEAR MEDICINE, ISSN 0363-9762, 02/2019, Volume 44, Issue 2, pp. E85 - E86
Here we report on the treatment of a 38-year-old woman with primary cutaneous gamma delta T-cell lymphoma, which is a rare subset of cutaneous T-cell lymphoma.... 
primary cutaneous gamma delta T-cell lymphoma | cutaneous T-cell lymphoma | F-18-fluorodeoxyglucose | spatial resolution | pralatrexate | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | PET
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.